> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Makary Warns ‘Illegal Copycat Drugs’ Will Face Swift Enforcement
- URL: https://www.fdaweb.com/makary-warns-illegal-copycat-drugs-will-face-swift-enforcement/
- Published: 2026-02-06T12:00:00.000Z
- Updated: 2026-09-14T15:32:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160622

FDA is pledging to move quickly against companies that mass-market “illegal copycat drugs” by portraying them as equivalent to FDA-approved medicines, commissioner **Marty Makary** says in an X social media post, presumably signaling a tougher enforcement posture that rattled investors in telehealth company Hims & Hers Health. Makary’s comments came shortly after Hims began selling a low-cost compounded pill it says is similar to Novo Nordisk’s newly approved GLP-1 weight-loss drug Wegovy (semaglutide).

Novo has threatened legal action ([see earlier story](https://www.fdaweb.com/telehealth-firm-undercuts-novo-glp-1-pill-price-reuters/)) against Hims and Hers and has called on regulators to control the compounding market that threatens its business.

“The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs,” Makary says in the post, underscoring the agency’s position that such products fall outside the legal framework governing approved medicines.

The episode has revived broader concerns about compounded versions of high-demand GLP-1 obesity drugs, which have proliferated as patients seek cheaper alternatives, a [report from Reuters](https://www.reuters.com/legal/litigation/fda-take-action-companies-marketing-illegal-copycat-drugs-fda-chief-says-2026-02-05/?ref=fdaweb.com) notes. Compounding pharmacies are permitted under U.S. law to prepare customized medications for individual patients, including altered dosages, but FDA officials and brand-name manufacturers have argued that large-scale “mass compounding” that mimics approved drugs crosses a legal line. Makary’s comments reinforced that view, framing copycat versions as unlawful rather than simply unregulated.

Hims said in a statement that it has not compromised on safety or efficacy and that its pill uses a liposome-based technology intended to support absorption. The company did not directly address the FDA’s characterization of copycat drugs as illegal, Reuters says.

Novo Nordisk dismissed the compounded alternative as ineffective, arguing that Novo’s pill relies on proprietary technology to enable absorption of the active ingredient. Eli Lilly, which is expected to launch its own GLP-1 pill later this year, did not comment directly on Makary’s statement, but analysts have warned that Lilly’s product could also become a target for compounded copies.

Hims previously sold compounded injectable versions of GLP-1 drugs during shortages, a practice FDA temporarily allowed, but the agency warned the company last year that its marketing of compounded semaglutide was misleading, including claims that it contained the “same active ingredient” as branded drugs like Ozempic and Wegovy.

With shortages having reportedly eased and new branded products entering the market, Makary’s warning suggests FDA is prepared to draw a firmer line. For companies promoting compounded alternatives as substitutes for approved medicines, the commissioner’s message was blunt: copycats are illegal, and enforcement is coming.